National Health Partners, Inc. (OTC:NHPR)
National Health Partners, Inc. currently offers five standard CARExpress membership programs that provide benefits that range from prescription drug and vision care to comprehensive physician, hospital, vision, dental and other care.
National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called "CARExpress." CARExpress is one of the largest networks of hospitals, doctors, dentists, pharmacists and other healthcare providers in the country and is comprised of over 1,000,000 medical professionals that belong to such PPOs as CareMark and Aetna. National Health Partners, Inc's primary target customer group is the 47 million Americans who have no health insurance of any kind. The company's secondary target customer group includes the millions of Americans who lack complete health insurance coverage. National Health Partners, Inc. is headquartered in Horsham, Pennsylvania.
As the saying goes change is not always good. Healthcare costs have been increasing across world in the past couple of years. One of the major reasons attributed to this is the changing lifestyle of people. Other common factors include genetic disorders, addictions, lack of knowledge on good nutrition and poverty. In some countries, healthcare has become inaccessible to people below poverty line. It has put a huge burden on the government.
National Health Partners, Inc. (OTC:NHPR), a leading provider of unique discount healthcare membership programs, announced that it has entered into agreement with a major Hispanic marketing group for the sale of its CARExpress programs. The company also sees growth in new sales of memberships of more than 300% thru the remainder of the year.
Under the new agreement, this national Hispanic marketing group will be promoting the company's CARExpress discount healthcare membership program to Hispanic communities located across the United States, with particular focus on cities and regions containing a large number of Hispanics. With the previously announced plans to increase monthly sales by 75% with its newest and most successful marketing partner, the company now expects sales of new members to grow more than 300% thru the remainder of the year.
For more information about National Health Partners, Inc. please visit their website: www.nationalhealthpartners.com.
American National Insurance Co. (Nasdaq:ANAT) board of directors declared a quarterly dividend of 77 cents per share on its common stock, CUSIP #028591-105, payable September 16, 2011 to shareholders of record as of the close of business on September 2, 2011. American National Insurance Company has paid dividends to stockholders for over 100 consecutive years.
American National Insurance Company, together with its subsidiaries, provides insurance products and services in the United States, the District of Columbia, Puerto Rico, Guam, and American Samoa.
Nash Finch Co. (Nasdaq:NAFC) announced that its board of directors has declared a regular quarterly cash dividend of 18 cents per share of common stock. The dividend is payable September 2, 2011 to shareholders of record at the close of business on August 19, 2011. It is the Company's 340th consecutive quarterly cash dividend. There are 12,136,507 shares of common stock outstanding.
Nash-Finch Company operates as a wholesale food distributor in the United States. The company's Military segment distributes grocery products to the United States military commissaries and exchanges in the United States and the District of Columbia, Europe, Puerto Rico, Cuba, the Azores, and Egypt.
Jazz Pharmaceuticals, Inc. (Nasdaq:JAZZ) announced financial results for the second quarter of 2011. Total revenues for the quarter ended June 30, 2011 were $64.6 million, compared to $40.5 million for the second quarter of 2010. Total revenues included net product sales, royalties and contract revenues. GAAP net income for the second quarter of 2011 was $33.2 million, or $0.71 per diluted share, compared to a GAAP net loss of $6.4 million, or $0.18 per diluted share, for the second quarter of 2010. The company's GAAP net loss in the second quarter of 2010 included a loss on extinguishment of debt of $12.3 million.
Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States.
Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) announced financial results for the second quarter of 2011 and provided an update on development programs and upcoming milestones. EYLEA, also known as VEGF Trap-Eye, is a fusion protein locally administered in the eye that is designed to bind Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PlGF), proteins that are involved in the abnormal growth of new blood vessels. Regeneron maintains exclusive rights to EYLEA in the United States. Bayer HealthCare LLC has rights to market EYLEA outside the U.S., where the companies will share equally in profits from any future sales of the product candidate.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States.
Signup for FREE Daily Stock Alerts From http://www.CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received 3,000,000 shares of (144) restricted common stock from the company and 3,000,000 shares of free trading shares from a third party (PIERRE BESUCHET) for six months of advertisement services for National Health Partners Inc. (OTC:NHPR).